Acme United Reports Third Quarter 2026 Net Sales Increase of 18%

Acme United posts record sales and strong profit growth, driven by acquisitions and margin gains.

What the company is saying

Acme United emphasizes record quarterly sales of $58.0 million, up 18% year-over-year, and net income of $3.4 million, an 80% increase. The company highlights broad-based growth across all business units and geographies, with Chairman and CEO Walter C. Johnsen attributing success to strong back-to-school demand and the ongoing integration of the My Medic acquisition. Management is transparent about the impact of one-time items: a $6.0 million IEEPA tariff refund, with $4.0 million recognized in Q3 as a cost reduction and $2.0 million accrued, and $1.8 million in costs for closing the DMT sharpening facility. The company notes that My Medic contributed to sales but had minimal earnings impact in Q3 due to seasonality, with most profitability expected in Q4. Johnsen also flags rising transportation and raw material costs, and outlines plans to close the DMT plant in Massachusetts later in 2026, expecting over $1.0 million in annual savings from 2027. The tone is confident, with repeated references to operational discipline, international growth, and ongoing acquisition strategy.

What the data suggests

The numbers show robust operational and financial momentum. Quarterly net sales rose to $58.0 million from $49.1 million, and nine-month sales reached $173.0 million, up from $149.0 million. Net income for the quarter jumped to $3.4 million from $1.9 million, with diluted EPS up to $0.80 from $0.46. Gross margin expanded sharply to 45.3% in Q3 2026 from 39.1% a year earlier, boosted by a 690 basis point benefit from tariff refunds, partly offset by 310 basis points of DMT closure costs. Free cash flow for the twelve months was $13.8 million, including $6.0 million in tariff refunds. Bank debt less cash increased to $29.7 million from $23.1 million, reflecting acquisition activity: $14.5 million paid for My Medic and $1.6 million for a German product line. Segment growth was strong: U.S. sales up 20% in Q3, European sales up 5% in USD (7% in local currency), and Canadian sales up 9% in USD (12% in local currency). The company distributed $2.4 million in dividends. The data confirms management's narrative of record sales and margin improvement, with clear disclosure of one-off items and acquisition impacts.

Analysis

The announcement is highly factual and proportionate to the company's actual performance. The majority of claims are realised and supported by detailed numerical disclosures, including net sales, net income, EPS, gross margin, and free cash flow. Forward-looking statements (such as expected savings from the DMT plant closure and future profitability from My Medic) are clearly separated from realised results and do not dominate the narrative. The tone is positive but justified by record sales, significant year-over-year profit growth, and improved margins. Capital outlays for acquisitions are disclosed, but the benefits from these investments are already reflected in current sales and operational results, with no exaggerated claims about future impact. There is no evidence of narrative inflation or overstatement.

Risk flags

• ●Rising transportation and raw material costs could pressure future margins, as explicitly acknowledged by management. This risk is heightened by ongoing global supply chain volatility and inflationary pressures.
• ●The integration of recent acquisitions, particularly My Medic, carries execution risk. While integration is said to be on plan, the full earnings impact is seasonal and concentrated in Q4, increasing exposure to any operational or market disruptions in that period.
• ●Closure of the DMT facility and shifting production offshore could result in transition challenges or unanticipated costs. Although annual savings of over $1.0 million are projected for 2027, realization depends on successful execution and stable supply from new facilities.
• ●Bank debt less cash has risen to $29.7 million from $23.1 million, reflecting increased leverage from acquisitions. While free cash flow remains strong, higher debt levels could constrain flexibility if operating conditions deteriorate.

Bottom line

Acme United delivered record sales and substantial profit growth in Q3 2026, supported by acquisitions, tariff refunds, and margin expansion. The company is executing on its strategy of international growth and operational consolidation, with the My Medic acquisition and a new German product line already contributing to top-line gains. One-off items such as the $6.0 million tariff refund and $1.8 million in restructuring costs are clearly disclosed, and the company expects further cost savings from the DMT facility closure in 2027. The main near-term catalyst is Q4, when My Medic's seasonality should drive additional profitability. Risks include cost inflation, integration execution, and higher leverage, but current disclosures are detailed and credible. The most important takeaway is that Acme United is translating acquisition and operational initiatives into tangible financial results, with further upside possible if Q4 delivers as expected.

Announcement summary

(NYSE:ACU) Acme United Corporation reported net sales of $58.0 million for the quarter ended September 30, 2026, compared to $49.1 million for the same period in 2025, representing an 18% increase. Excluding sales from the My Medic asset acquisition on January 15, 2026, comparable three-month sales increased 10%. Net sales for the nine months ended September 30, 2026, were $173.0 million, up from $149.0 million in 2025, an increase of 16%; excluding My Medic, comparable nine-month sales increased 8%. Net income for the quarter was $3.4 million, or $0.80 per diluted share, compared to $1.9 million, or $0.46 per diluted share, in 2025, an increase of 80% in net income and 74% in diluted EPS. Net income for the nine months ended September 30, 2026, was $9.5 million, or $2.29 per diluted share, compared to $8.3 million, or $2.03 per diluted share, in 2025, an increase of 14% in net income and 13% in diluted EPS. Chairman and CEO Walter C. Johnsen stated that the company achieved record sales in the quarter, with growth across all business units and internationally, and that the My Medic integration is progressing as planned. The company applied for and received $6.0 million in IEEPA tariff refunds, recognizing $4.0 million as a reduction of cost of goods sold in Q3 2026, with the remaining $2.0 million recorded as an accrued liability. In Q3 2026, $1.0 million of variable compensation expense related to the refund was included in SG&A expenses. The company accrued $1.8 million in costs related to the closure of the DMT sharpening facility and the move of DMT production to more cost-effective facilities in Asia. Net income for the three- and nine-month periods included approximately $0.4 million of tax benefits from stock option exercises. The My Medic business, acquired in January 2026, contributed to sales growth but had minimal impact on earnings in Q3 and the first nine months due to seasonality, with most profitability expected in Q4. The company plans to close the DMT plant in Massachusetts later in 2026 and shift production and fulfillment to other locations and offshore, with annual savings from the closure expected to exceed $1.0 million in 2027. For Q3 2026, U.S. segment net sales increased 20% year-over-year, and for the nine months ended September 30, 2026, U.S. segment net sales increased 17%. European net sales for Q3 2026 increased 5% in U.S. dollars and 7% in local currency, and for the nine months increased 20% in U.S. dollars and 15% in local currency, driven by higher ecommerce sales and the acquisition of a cutting and sharpening product line in Germany on October 1, 2025. Canadian net sales for Q3 2026 increased 9% in U.S. dollars and 12% in local currency, and for the nine months increased 8% in both U.S. dollars and local currency, due to higher first-aid product sales. Gross margin was 45.3% in Q3 2026 versus 39.1% in Q3 2025, with a benefit of approximately 690 basis points from the tariff refund, partially offset by 310 basis points from DMT closure costs. Gross margin for the nine months ended September 30, 2026, was 42.6% compared to 39.8% in 2025, with a benefit of 230 basis points from the tariff refund and an offset of 105 basis points from DMT closure costs. Bank debt less cash as of September 30, 2026, was $29.7 million compared to $23.1 million as of September 30, 2025. During the twelve months ended September 30, 2026, the company paid approximately $14.5 million for the My Medic asset acquisition ($18.6 million purchase price less $4.1 million of holdbacks), distributed approximately $2.4 million in dividends, and purchased the cutting and sharpening line in Germany for approximately $1.6 million. The company generated approximately $13.8 million in free cash flow during the same period, including $6.0 million in tariff refunds. As of September 30, 2026, cash and cash equivalents were $7.9 million, accounts receivable were $36.2 million, and inventories were $69.0 million. Total assets were $207.9 million and total stockholders' equity was $124.9 million as of September 30, 2026.

Disagree with this article?